Clinical trials: Neoplasia Prostate
Prostate Cancer
Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)
This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer.
- Trial name
- ProGen (NCT03328091)
- Testing
- Traditional pre-test genetic counseling, Pre-test video education
- Where
- 3 sites in United States
- Volunteers
- 662 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms
Exisulind Prior to Radical Prostatectomy
This trial will compare no treatment to exisulind therapy. Patients enrolled on the treatment arm will begin treatment 4 weeks prior to the scheduled date of surgical removal of the prostate and will take 375 mg by mouth daily…
- Trial name
- NCT00166478
- Testing
- Exisulind Therapy
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Mayo Clinic
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score.
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04513717
- Testing
- Apalutamide, Bicalutamide, Biospecimen Collection
- Where
- 602 sites in United States, Canada
- Volunteers
- 2,753 people
- Sponsor
- NRG Oncology
Diagnoses Disease
Micro-Ultrasound/Magnetic Resonance Imaging 001
Micro-ultrasound is a novel real-time imaging modality which maintains the clinical workflow of conventional ultrasound-guided prostate biopsy, while potentially maintaining a similar ability to detect clinically significant…
- Trial name
- NCT03938376
- Testing
- Micro-Ultrasound guided biopsy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer, Urological Cancer
Evaluation of the PI-RADS v2.1 Score Using Multiple Readers
The interpretation of prostate multiparametric MRI (mpMRI) is difficult and requires expertise. As a result, it suffers from substantial inter-reader variability.
- Trial name
- MULTI (NCT04299997)
- Testing
- Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients
The objective of this study is to evaluate the feasibility of two different chemotherapy protocols with adjusted doses for patients aged 75 and over who often have medical problems other than prostate cancer.
- Trial name
- GERICO10 (NCT01254513)
- Testing
- Docetaxel every 3 weeks + Prednisone, Docetaxel weekly+ Prednisone
- Where
- 31 sites in France
- Volunteers
- 66 people
- Sponsor
- UNICANCER
Prostate Carcinoma
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion…
- Trial name
- ECLIPSE (NCT07185165)
- Testing
- Computed Tomography, Fluorine F 18 Flotufolastat, Positron Emission Tomography
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostatic Neoplasms
Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)
The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.
- Trial name
- PROPELLER (NCT04839367)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 3 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
In this study, ASP5541 will be given to Chinese men with prostate cancer. It will be given together with prednisone and androgen deprivation therapy (ADT).
- Conditions
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
- Trial name
- NCT07339267
- Testing
- ASP5541, Prednisone
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment, and Lutetium 177Lu-prostate specific-membrane antigen…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06039371
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Washington
Prostate Carcinoma
A Prospective, Single-centre，Single-blinded Study of PROUD for Prostate Carcinoma Diagnosis
Prostate carcinoma (PC) is common malignancy and is considered to be the highest incidence in the old males. The traditional diagnostic methods of PC present with some shortcomings.
- Trial name
- NCT04699344
- Testing
- The level of CNV
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Qilu Hospital of Shandong University
Prostate Cancer
Focal Therapy for Localized Prostate Cancer
To evaluate the cancer control for prostate cancer patients treated with focal therapy.
- Trial name
- NCT03970863
- Testing
- Prostate Health Index
- Where
- Taiwan
- Sponsor
- China Medical University Hospital
Prostate Cancer, Molecular Imaging
Molecular Profiling of MRI-PSMA PET Discordance in Prostate Cancer
MRI and PSMA-PET are highly sensitive imaging tools for prostate cancer, yet they often detect different lesions. These discordant findings pose clinical uncertainty because their biological significance is unclear.
- Conditions
- Prostate Cancer, Molecular Imaging, Transcriptomics, RNA
- Trial name
- MP-PET-MRI (NCT07485257)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
Prostate Cancer
Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer
High risk prostate cancer (PCa) had worse outcomes on radical treatment results, short-time oncological results, even cancer-specific survival, than those low or mediate risk PCa.
- Trial name
- NCT04356430
- Testing
- Abiraterone Acetate, Prednisone, Goserelin 10.8 mg
- Where
- China
- Volunteers
- 75 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
The BIOPRES Trial: Transrectal BIOpsies of the PRostate: End Versus Side-firing
The purpose of this study is to study the difference in prostate cancer between two prostate biopsy techniques, namely end-firing and side-firing. These differ in the angle at which the prostate is biopsied.
- Trial name
- BIOPRES (NCT00851292)
- Testing
- TRUS probe
- Where
- Netherlands
- Volunteers
- 800 people
- Sponsor
- Amphia Hospital
Prostate Cancer
Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
18F-labeled prostate-specific membrane antigen (PSMA) ligand-positron emission tomography (PET) offers advantages over 68Ga-labeled PSMA ligands. Al18F-PSMA-617 is a novel 18F-PSMA compound used for prostate cancer (PCa) imaging.
- Trial name
- NCT05841992
- Testing
- Al18F-PSMA-617, 68Ga-PSMA-617
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer, Castration Sensitive Prostate Cancer
Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery
The purpose of this study is to characterize the reduction in PSMA-avid tumor volume and metastasis-directed radiotherapy treatment intensity facilitated by PET PSMA-response adapted SABR for poly-metastatic castration sensitive…
- Conditions
- Prostate Cancer, Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer, Adaptive Radiotherapy
- Trial name
- RIPCORD (NCT07674771)
- Testing
- Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
The active ingredient of Pamorelin® 11,25 mg is Triptorelin. Triptorelin is a substitute for a natural hormone produced in the body called Gonadotrophin-releasing hormone (GnRH).
- Trial name
- NCT00444639
- Testing
- Triptorelin (Decapeptyl®)
- Where
- 15 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Ipsen
Prostatic Neoplasms
Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer
Biochemical recurrence develops in approximately 30-40% of men with locally advanced prostate cancer who undergo radical prostatectomy.
- Trial name
- NCT01759836
- Testing
- Atorvastatin 20mg
- Where
- South Korea
- Volunteers
- 364 people
- Sponsor
- Asan Medical Center
Prostatic Neoplasms
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate pharmacokinetics (PK) following a single dose and multiple dose treatment and the safety of apalutamide in Chinese participants with metastatic castration resistant prostate cancer (mCRPC)…
- Trial name
- NCT03523442
- Testing
- Apalutamide
- Where
- 4 sites in China
- Volunteers
- 19 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.